Exhibit 99.2

PrestigeBrands



Review of Third Quarter F'12 Results

Matthew M. Mannelly, CEO Ronald M. Lombardi, CFO

February 9, 2012

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's acquisition strategy, ability to integrate acquisitions, the impact of acquisitions on the company's operating results and financial condition, the company's ability to repay debt, growth strategies, investments in advertising and promotion, market position, product introductions and innovations, and future financial performance. Words such as "continue," "will," "believe," "intend," "expect," "anticipate," "plan," "potential," "estimate," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the failure to successfully commercialize new and enhanced products or integrate new product acquisitions, the effectiveness of the Company's advertising and promotions investments, continuing decline in the household cleaning products market, the severity of the cold/cough season, the effectiveness of the Company's marketing and distribution infrastructure, and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2011. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable securities laws, the Company undertakes no obligation to update any forward-looking statement contained herein, whether as a result of new information, future events, or otherwise.



Third Quarter Highlights

- Solid financial performance for Q3
 - Q3 revenue of \$106.3 million, up 17.3%, or \$15.7 million over the prior year comparable quarter
 - Revenue growth of over 3% for Core OTC brands in the aggregate, the sixth consecutive quarter of growth
 - EPS, excluding adjustments⁽¹⁾, was \$0.25 compared to the prior year's \$0.21, up 19%
 - FCF of \$14.5 million⁽²⁾ Debt reduced by \$18.0 million
- Core OTC strategy continues to deliver
 - Core OTC brands continue to outgrow categories in consumption and gain market share
 - Strong performance despite challenging cough/cold season
- Subsequent to the close of Q3
 - The largest acquisition in PBH history 15 brands from GSK, closed on January 31, 2012
 - Completed financing of additional bond & bank debt of \$250 and \$660 million ,respectively, to fund the acquisition of the GSK brands and expenses
 - Moody's and S&P ratings remain unchanged


⁽²⁾ Free Cash Flow is a non-GAAP financial measure and is reconciled to GAAP Net Cash provided by operating activities in our earnings release in the "About Non-GAAP Financial Measures" section.



⁽¹⁾ These adjustments are non – GAAP and are included in the reconciliation in our earnings release in the "About Non-GAAP Financial Measures" section.

Delivering Consistent Organic Core OTC Growth In a Challenging Environment


Six Straight Quarters of Organic Core OTC Growth Excluding Acquisitions



Dollar values in millions


PrestigeBrands

Driving Consumption That Has Consistently Exceeded The Categories, Leading to Solid Company Sales Growth



Dollar values in millions Notes: Consumption is based on IRI (FDM) for 12 week period ending December 25, 2011.

PBH Cough/Cold Brands: Strong Performance +7.2%⁽¹⁾ Despite Soft Start To Cough/Cold Season (-6.5%)⁽²⁾



(1) Based on IRI Consumption Data (FDM) for the 12 week period ending December 25, 2011.

(2) Source: FAN National 2011-2012 Weekly % Change vs. Same Week Last Year: Total, Adult & Pediatric.



Little Remedies: Portrait of a Brand On The Move

Tag Line: "Everything Kids Need And Nothing They Don't"

Target Audience: Parents and caregivers who prefer products with no artificial ingredients

Consumption: Up almost 15% for Q3 and 39% fiscal YTD⁽¹⁾

Media & Marketing Tools Used:





(1) Based on IRI Consumption Data (FDM) for the 12 week period ending December 25, 2011.



Point Of Purchase Displays






Luden's: Over 100 Years Old And Still Young

Tag Line: "Surprisingly soothing. Simply delicious."
Target Audience: Sufferers of minor throat irritation, all ages
Consumption: Up slightly for the period and almost 7% YTD⁽¹⁾







(1) Based on IRI Consumption Data (FDM) for the 12 week period ending December 25, 2011.



Household Stabilizing Effort Includes New Product Introductions in Q4



Introducing New Comet Stainless Steel Cleaners!

- Today's homes and consumers need specialty cleaners
- Available in Cream, Powder and Spray for multi-surface cleaning
- Increases Comet shelf position and importance to retailers



The Transformed Prestige Began February 1, 2012

- OTC Portfolio Sales have grown from \$200M to \$500M and increased from 57% to 85% of total Sales in the last two years: by mid 2012, we will have 13 Core OTC Brands and two new scale OTC platforms.
- The Transformed Prestige:
 - We are stronger, more diverse in our OTC businesses
 - More innovative in new product development
 - More creative in our marketing and advertising investments
 - And more in touch with our consumers and retail customers than ever before
- Our Balance Sheet is strong; our Free Cash Flow⁽¹⁾ is robust.
- Our disciplined strategy to create long-term shareholder value is working: drive core OTC organic growth, focus on OTC M&A activity, and strategically manage our portfolio.
- Timely and seamless integration of GSK brands is bolstered by our past experience in transitioning acquisitions into our organization
- We are pleased with Q3 results, and remain cautiously optimistic for Q4 given the current economic climate and the soft cough / cold season to date.
- The GSK acquisition is expected to add ~\$30M in Revenues and be EPS neutral in Q4, excluding adjustments⁽²⁾

- Q4 and Q1 transition period for Sales and A&P execution move to PBH.



⁽¹⁾ Refer to note 2 on page 3 related to non-GAAP Free Cash Flow.(2) Refer to note 1 on page 3 related to non-GAAP adjustments.


Financial Overview

Ronald M. Lombardi, CFO



Consistent Financial Performance

- A&P investment behind core OTC brands driving share and revenue gains. Beginning to "comp" Blacksmith acquisition.
- Revenue gains driving Net Income and EPS growth.
- Consistent cash flow from operations, with prior year favorably impacted by the Blacksmith acquisition.



Dollar values in millions, except per share data

(1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the "About Non-GAAP Financial Measures" section. Adjusted EPS is also reconciled to reported EPS on Slide 15.



Consolidated Financial Summary

	3 Months Ended		%
	Q3 '12	Q3 '11	Change
Net Revenue	\$106.3	\$90.6	17.3%
Gross Profit	55.1	47.6	15.9%
% Margin	51.9%	52.5%	2010 /0
A&P	15.3	13.0	17.1%
% of Net Revenue	14.4%	14.4%	17.170
G&A	8.8	8.5	3.1%
% of Net Revenue	8.2%	9.4%	5.170
(1) Adjusted EBITDA	31.1	26.0	19.5%
~ % Margin	29.3%	28.7%	
 (1) Adjusted Net Income (1) Adjusted EPS 	\$12.5 \$0.25	\$10.3 \$0.21	21.5% 19.0%
EPS - As Reported	\$0.19	\$0.04	375.0%

- Net Revenue grew by \$15.6 million, or 17.3%, over year ago.
 - 3.2% growth in legacy core OTC.
 - Acquisitions added \$16.6 million.
 - Excluding acquisitions, revenues (\$1.0 million) as overall OTC gains were offset by a soft start to cough / cold season and lower HH revenue.
- Gross margin was consistent with the previous four quarters and, as expected, below prior year due to the Blacksmith acquisition and HH.
- A&P investment continues to drive growth. G&A is consistent with prior year.
- Adjusted Net Income(1) and Adjusted EPS(1) tracking revenue gains.



Dollar values in millions, except per share data

(1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the "About Non-GAAP Financial Measures" section. Adjusted Net Income and Adjusted EPS are also reconciled to their reported GAAP amounts on Slide 15.

Consolidated Financial Summary

	9 Months Ended		%	
	Q3 '12	Q3 '11	Change	
Net Revenue	\$307.1	\$240.1	27.9%	
Gross Profit % Margin	158.9 <i>51.7%</i>	128.1 <i>53.3%</i>	24.0%	
A&P % of Net Revenue	38.6 <i>12.6%</i>	28.8 <i>12.0%</i>	34.1%	
G&A % of Net Revenue	26.7 <i>8.7%</i>	24.0 <i>10.0%</i>	11.2%	
(1) Adjusted EBITDA	93.6	75.3	24.3%	
% Margin	30.5%	31.4%		
 (1) Adjusted Net Income (1) Adjusted EPS 	\$37.3 \$0.74	\$30.9 \$0.62	20.4% 19.4%	
EPS - As Reported	\$0.73	\$0.45	62.2%	

Net Revenue grew by \$67 million,
or 27.9%, over year ago.

- 5.7% growth in legacy core OTC.
- Acquisitions added \$68.7 million.
- As expected, gross margin was 1.6 ppt lower than last year largely due to the impact of the acquired Blacksmith Brands and HH.
- A&P investment continues to drive growth.
- G&A increased \$2.7 million due to the impact of acquisitions and headcount additions to support growth.
- Adjusted Net Income(1). increased by 20.4% after certain adjustments(2).

Dollar values in millions, except per share data

(1) These non-GAAP financial measures are reconciled to their most closely related GAAP financial measures in our earnings release in the "About Non-GAAP Financial Measures" section. Adjusted Net Income and Adjusted EPS are also reconciled to their reported GAAP amounts on Slide 15.



(2) Refer to note 1 on page 3 related to non-GAAP adjustments.

Net Income and EPS Reconciliation

	3 Months Ended Q3 FY 2012		9 Months Ended Q3 FY 2012	
	Net		Net	
	Income	EPS	Income	EPS
⁽¹⁾ Q3 FY 2012 Adjusted	\$12.5	\$0.25	\$37.3	\$0.74
(2) Adjustments:				
Lawsuit Settlement net of Professional Fees			4.3	0.08
Acquisition Related Costs	(4.9)	(0.10)	(4.9)	(0.10)
Tax Impact of Adjustments	1.9	0.04	0.3	0.01
Tax Rate Adjustment			0.2	0.00
Total Adjustments	(3.0)	(0.06)	(0.1)	(0.01)
Q3 FY 2012 As Reported	\$9.5	\$0.19	\$37.2	\$0.73

Dollar values in millions, except per share data

(1) These non-GAAP financial measures are being reconciled to their most closely related GAAP financial measures. For further information about non-GAAP financial measures, refer to our earnings release in the "About Non-GAAP Financial Measures" section.



(2) Refer to note 1 on page 3 related to non-GAAP adjustments.

Prestige Strength: Cash Flow from Operations

_	3 Months Ended		9 Months Ended	
-	Q3 '12	Q3 '11	Q3 '12	Q3 '11
Net Income	\$9.5	\$2.2	\$37.2	\$22.8
Depreciation & Amortization	2.6	2.5	7.7	7.6
Other Non-Cash Operating Items	2.5	1.8	11.2	10.9
Working Capital	(0.1)	12.3	(8.1)	20.4
Cash Flow from Operations	\$14.5	\$18.8	\$48.0	\$61.7

 Quarterly and Year-to-Date Cash Flow From Operations are impacted by this year's higher sales volumes and the impact of the Blacksmith acquisition on the prior year's results.

Debt Profile & Covenant Compliance:

- Total Indebtedness at 12/31/11, \$434 million, reflects a Q3 pay down of \$18.0 million and \$58.0 million for the year to date.
- The company is compliant with all covenant requirements.

Dollar values in millions



PBH Purchases OTC Brands from GSK





GSK Transaction Strengthens Prestige's Strategic and Financial Profile

- Strengthens Core OTC by adding new brands and category depth
- Reduces sensitivity to seasonality of Cough/Cold brands
- OTC now represents 85% of sales and 90% of contribution

Financial

- Accretive to gross margins and EBITDA margins
- Increases A&P support with focus on Core brands
- Highly cash generative and accretive to free cash flow



GSK Transaction Adds Four Core Brands That Strengthen Prestige's Existing Platforms

% of PF Revenue:








Note: The remaining 20% of sales is comprised of Household (including Comet) and other brands.



Acquisitions Transform PBH; 90% of Contribution Margin Now From OTC









GSK Transaction Creates a Larger, More Diversified and Competitive Business

	Pre-Transaction	Post-Transaction
Revenues	~\$400	~\$600
Key Category Platforms	4	6
Core Brands	9	13
A&P Spending	~12%	~14%
Margins	~32%	~35%
Cash Flow from Operations	~\$75 MM	~\$ 110 MM



Dollar values in millions

Four New Core Brands

- BC/Goody's Headache Powders & Pain Relievers
 - Unique 80 year southern heritage with ~ 16% share in Southern market
 - #1 share of powdered aspirin segment
 - Rivalry ad campaign driven by heavy radio support in southern markets; Richard Petty and Trace Adkins; NASCAR sponsor
 - Strong C store presence The Number 1 OTC products sold in Southern C stores
 - Opportunities: distribution, new products, promotion
- Beano Gas Prevention
 - 85% share of growing gas prevention segment
 - Unique oral meltaway tablet
 - Opportunities: focus on prevention, innovation, distribution, A&P
- Debrox Ear Wax Remover
 - Category leader and #1 most recommended by doctors and pharmacist
 - Shopper marketing initiatives to drive revenue
 - Opportunities: continue strong A&P support and drive innovation of new products
- Gaviscon Antacid (Canada)
 - #1 Doctor recommended OTC for acid reflux and fastest growing antacid in category
 - TV campaign is driving sales performance
 - Excellent retail presence and distribution in Canada
 - Opportunities: Pursue new users and "switchers" from other brands; focus on competitive claims












Prestige <u>Strengthens</u> Industry Leading Margins and Free Cash Flow Conversion



Source: Capital IQ

(1) Represents nine months ending December 2011 for Prestige; Represents LTM period for all others.

(2) Free Cash Flow is a non GAAP financial measure and is defined as Operating Cash Flow less Capital Expenditures.

High Cash Flow Conversion Expected to Lead to Continued Rapid Deleveraging

Leverage Ratio // = Excluding Acquisitions GlaxoSmithKline 6.1x WARTNER. < 5.5x < 5.0x 4.7x 4.6x Dramamine⁻ 4.3x ////// ~4.0x ////// 4.1x 3.9x 4.4x 4.4x 3.5x ~3.5x 3.2x 3.8x 3.5x ~2.5x 3.1x > 2.0x 2.2x Pre-IPO LTM 2015 2005 2006 2007 2008 2009 2010 Pro 2013 2014 2016 2017 12/31Forma

Fiscal Year

Fiscal year ending March 31 Leverage ratio reflects Net Debt / EBITDA Source: CapitalIQ



Financing Well Received By Market






Financing Overview


Senior Unsecured Notes	 \$250 million Senior Unsecured Notes Coupon: 8.125% Tenor: 8 Years Guarantors: Jointly and severally guaranteed on a senior basis Redemption: NC-4, then callable with a premium of 1/2 coupon in year 5, 1/4 coupon in year 6 and par thereafter CIC: Put to issuer at 101% Equity Clawback: Up to 35%, within the first three years
Senior Secured Credit Facility	 \$660 million Senior Secured Term Loan B Facility ("TLB") Margin: L (Floor 1.25%) + 400 bps Tenor: 7 Years Covenants: 1. Maximum Consolidated Total Net Leverage Ratio, may net up to \$75M cash 2. Minimum Consolidated Net Cash Interest Coverage Ratio Amortization: 1% per annum paid quarterly, with remainder due at maturity
Asset Based Revolving Facility	 \$50 million Senior Secured Asset Based Revolving Facility ("ABL") Margin: L (no floor) + 175 to 225 bps Tenor: 5 Years Security: First priority lien on ABL Collateral, second priority lien on TLB Collateral



Proven Track Record of Successful Integrations



Robust Integration Planning & Processes Leverage Deep Experience and Extensive Diligence Effort





Detailed Transition Plan in Process at Close

Our track record of seamless integration of acquired brands allows for a smooth and rapid transition of the GSK brands

Science & Technology	Supply Chain	Marketing & Sales			
 Transfer of licenses, product documentation, and product claim support QA: Day to day oversight by PBH of inventory providers; establish new quality agreements with third party manufacturers Regulatory: update licenses, filings and artwork on all brands 	 3+ year supply from GSK site eliminates up-front transfers 5 month TSA consolidation plan currently underway 	 Integrate and realign sales structure across classes of trade and core customers Canada: opportunity as a result of doubling the business Expand and secure distribution base: C-store & club opportunities Increase marketing support for new core brands – BC/Goody's, Beano, Gaviscon and Debrox; Agencies already onboard 			
Finance & IT					
 Business runs on GSK systems initially during transition period Current system can accommodate GSK acquisition with minor upgrades Data transfer currently underway Integrate financial data day one Inventory planning and management system Sales reporting and analysis 					



Acquisition and Integration Costs

	Actual Q3 FY 2012	Estimate Q4 FY 2012
(1) Adjustments		
Acquisition Related Deal Costs Integration Costs TSA Costs Purchase Accounting - Inventory Other Costs - Write off of 2010 Fin Tax Impact of Adjustments Total Adjustments	\$ 4.9 ance Costs <u>(1.9)</u> \$ 3.0	\$ 11.0 2.0 4.5 2.5 5.0 (9.7) \$15.3
EPS Impact	\$ (0.06)	\$ (0.30)

Dollar values in millions, except per share data

(1) Refer to note 1 on page 3 related to non-GAAP adjustments.

Well Positioned to Create Long Term Shareholder Value





Clear Roadmap for Value Creation




Exhibit 99.2





February 9, 2012